IGM Biosciences, Inc. (NASDAQ:IGMS) Expected to Earn Q2 2025 Earnings of ($0.38) Per Share

IGM Biosciences, Inc. (NASDAQ:IGMS) – Analysts at Wedbush issued their Q2 2025 EPS estimates for shares of IGM Biosciences in a research report issued on Tuesday, October 1st. Wedbush analyst R. Driscoll forecasts that the company will post earnings per share of ($0.38) for the quarter. Wedbush has a “Outperform” rating and a $22.00 price target on the stock. The consensus estimate for IGM Biosciences’ current full-year earnings is ($3.13) per share. Wedbush also issued estimates for IGM Biosciences’ Q3 2025 earnings at ($0.40) EPS and Q4 2025 earnings at ($0.40) EPS.

Other research analysts also recently issued research reports about the stock. Truist Financial downgraded shares of IGM Biosciences from a “buy” rating to a “hold” rating and cut their price objective for the stock from $24.00 to $12.00 in a research report on Tuesday. Guggenheim lowered their target price on shares of IGM Biosciences from $25.00 to $20.00 and set a “buy” rating for the company in a research note on Tuesday. JPMorgan Chase & Co. lowered shares of IGM Biosciences from a “neutral” rating to an “underweight” rating and cut their price target for the company from $12.00 to $9.00 in a research note on Tuesday. Royal Bank of Canada lowered their price target on IGM Biosciences from $20.00 to $17.00 and set an “outperform” rating for the company in a research report on Tuesday. Finally, HC Wainwright lowered their target price on IGM Biosciences from $12.00 to $11.00 and set a “neutral” rating on the stock in a research note on Thursday, September 5th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat, IGM Biosciences has an average rating of “Hold” and a consensus target price of $14.67.

IGM Biosciences Price Performance

Shares of IGMS stock opened at $14.50 on Wednesday. The stock’s 50-day moving average is $11.65 and its 200 day moving average is $9.75. IGM Biosciences has a 1-year low of $3.81 and a 1-year high of $22.50. The company has a market cap of $855.85 million, a P/E ratio of -3.36 and a beta of 0.19.

IGM Biosciences (NASDAQ:IGMS) last released its quarterly earnings data on Wednesday, August 14th. The company reported ($0.79) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.18 by ($0.97). The business had revenue of $1.25 million for the quarter, compared to the consensus estimate of $51.75 million. IGM Biosciences had a negative net margin of 7,571.35% and a negative return on equity of 119.02%.

Insiders Place Their Bets

In related news, Director Julie Hambleton sold 15,132 shares of the firm’s stock in a transaction dated Thursday, July 25th. The shares were sold at an average price of $14.00, for a total value of $211,848.00. Following the transaction, the director now directly owns 2,000 shares of the company’s stock, valued at approximately $28,000. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In other news, CEO Fred Schwarzer sold 3,946 shares of the company’s stock in a transaction that occurred on Friday, September 13th. The stock was sold at an average price of $11.54, for a total value of $45,536.84. Following the completion of the sale, the chief executive officer now directly owns 250,124 shares in the company, valued at $2,886,430.96. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Julie Hambleton sold 15,132 shares of the stock in a transaction that occurred on Thursday, July 25th. The shares were sold at an average price of $14.00, for a total value of $211,848.00. Following the completion of the sale, the director now directly owns 2,000 shares of the company’s stock, valued at approximately $28,000. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 21,034 shares of company stock worth $279,957. Company insiders own 57.00% of the company’s stock.

Institutional Trading of IGM Biosciences

Large investors have recently added to or reduced their stakes in the stock. Baker BROS. Advisors LP increased its position in IGM Biosciences by 10.8% during the first quarter. Baker BROS. Advisors LP now owns 4,088,322 shares of the company’s stock worth $39,452,000 after purchasing an additional 397,311 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its position in IGM Biosciences by 19.3% in the first quarter. Price T Rowe Associates Inc. MD now owns 3,888,023 shares of the company’s stock valued at $37,520,000 after buying an additional 628,001 shares during the last quarter. Redmile Group LLC increased its position in shares of IGM Biosciences by 3.4% during the first quarter. Redmile Group LLC now owns 3,072,478 shares of the company’s stock valued at $29,649,000 after acquiring an additional 100,936 shares during the last quarter. TD Asset Management Inc raised its stake in shares of IGM Biosciences by 3.4% in the 2nd quarter. TD Asset Management Inc now owns 164,472 shares of the company’s stock valued at $1,130,000 after acquiring an additional 5,350 shares during the period. Finally, Renaissance Technologies LLC raised its position in IGM Biosciences by 126.0% in the second quarter. Renaissance Technologies LLC now owns 108,693 shares of the company’s stock valued at $747,000 after purchasing an additional 60,593 shares during the period. 42.79% of the stock is currently owned by hedge funds and other institutional investors.

IGM Biosciences Company Profile

IGM Biosciences, Inc, a clinical-stage biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer and autoimmune and inflammatory diseases. It develops Aplitabart, a Death Receptor 5 Agonist IgM antibody for the treatment of colorectal cancer; imvotamab, a CD20 x CD3 bispecific IgM antibody to treat myositis, as well as for the treatment of systemic lupus erythematosus and rheumatoid arthritis that is Phase Ib clinical trial; and IGM-2644, a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins for the treatment of autoimmune diseases.